Plus Therapeutics, INC Form 4 insider transactions

Es-Johansson An Van, a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Richard J Hawkins, a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Andrew John Hugh Macintyre Sims, Chief Financial Officer of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Howard Clowes, a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Marc H Hedrick, Chief Executive Officer and a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Ronald Asbury Andrews, a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Kyle Guse, a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.

Kyle Guse, a Director at Plus Therapeutics, Inc., acquired 922 shares of common stock through the vesting of Restricted Stock Units.

Ronald Andrews, a Director at Plus Therapeutics, Inc., reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026, as per SEC Form 4 filing.

Plus Therapeutics, Inc. director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026.

Marc Hedrick, CEO of Plus Therapeutics, reports on the vesting of Restricted Stock Units (RSUs) on July 1, 2026, increasing his beneficial ownership of common stock.

An van Es-Johansson, a Director at PLUS THERAPEUTICS, INC., has acquired restricted stock units and stock options.

Richard J. Hawkins, a Director at Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Plus Therapeutics, Inc. reports a Form 4 filing detailing the acquisition of stock options and restricted stock units by Director Kyle Guse.

Director Howard Clowes of Plus Therapeutics, Inc. acquired stock options and restricted stock units, indicating continued commitment and potential future equity.

Ronald Asbury, a Director at PLUS THERAPEUTICS, INC., reported transactions involving the acquisition of restricted stock units and stock options.

Andrew Sims, Chief Financial Officer of Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Marc Hedrick, CEO of Plus Therapeutics, reported transactions involving restricted stock units and stock options on May 14, 2026.

Chief Development Officer Eric Joseph Daniels received a grant of 20,000 restricted stock units and 20,000 stock options.

PLUS THERAPEUTICS, INC. Chief Financial Officer, Andrew Sims, reported the vesting of 67,452 Restricted Stock Units into common stock.

PLUS THERAPEUTICS CEO Marc H. Hedrick reported future vesting of Restricted Stock Units, impacting his beneficial ownership of common stock.

Plus Therapeutics CFO Andrew Sims reported the acquisition of 349,542 Restricted Stock Units and 349,541 stock options, increasing his beneficial ownership.

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick received 2,419,582 Restricted Stock Units and 2,419,582 stock options, aligning executive incentives with long-term company performance.

PLUS THERAPEUTICS CEO Marc H. Hedrick reported the vesting of 159,681 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

PLUS THERAPEUTICS CFO Andrew Sims acquired 38,323 shares of common stock through the vesting of Restricted Stock Units on January 1, 2026.

PLUS THERAPEUTICS CFO Andrew Sims acquired 20,000 shares of common stock at an average price of $0.51.

PLUS THERAPEUTICS CFO Andrew Sims filed an amended Form 4 to correct the vesting schedule for 459,878 Restricted Stock Units.

PLUS THERAPEUTICS CEO Marc H. Hedrick reported the vesting of 159,681 Restricted Stock Units, converting them into common stock.

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick filed an amended Form 4 to correct the vesting schedule for his Restricted Stock Units.

PLUS THERAPEUTICS CFO Andrew Sims reported the vesting of 38,323 Restricted Stock Units, increasing his direct beneficial ownership of common stock.